K
Kiyoko Iwatsuki-Horimoto
Researcher at University of Tokyo
Publications - 111
Citations - 7279
Kiyoko Iwatsuki-Horimoto is an academic researcher from University of Tokyo. The author has contributed to research in topics: Virus & Medicine. The author has an hindex of 32, co-authored 79 publications receiving 4640 citations.
Papers
More filters
letters-and-commentsDOI
In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6
Emi Takashita,Seiya Yamayoshi,Peter Halfmann,Nancy A. Wilson,Hunter Ries,Alex Richardson,M. Bobholz,W. Vuyk,Robert Maddox,David A. Baker,Thomas C. Friedrich,David H. O’Connor,Ryuta Uraki,Mutsumi Ito,Yuko Sakai-Tagawa,Eisuke Adachi,Makoto Saito,Michiko Koga,Takeya Tsutsumi,Kiyoko Iwatsuki-Horimoto,Maki Kiso,Hiroshi Yotsuyanagi,Shinji Watanabe,Hideki Hasegawa,Masaki Imai,Yoshihiro Kawaoka +25 more
Journal ArticleDOI
Potent SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models
Masaru Takeshita,Hidehiro Fukuyama,Katsuhiko Kamada,Takeshi Matsumoto,Chieko Makino-Okamura,Tomomi Uchikubo-Kamo,Yuri Tomabechi,Kazuharu Hanada,Saya Moriyama,Yoshimasa Takahashi,Hirohito Ishigaki,Misako Nakayama,Cong Thanh Nguyen,Yoshinori Kitagawa,Yasushi Itoh,Masaki Imai,Tadashi Maemura,Yuri Furusawa,Hiroshi Ueki,Kiyoko Iwatsuki-Horimoto,Mutsumi Ito,Seiya Yamayoshi,Yoshihiro Kawaoka,Mikako Shirouzu,Makoto Ishii,Hideyuki Saya,Yasushi Kondo,Yuko Kaneko,Tatsuya Suzuki,Koichi Fukunaga,Y. Takeuchi +30 more
TL;DR: In this paper , the authors created 494 monoclonal antibodies from patients with COVID-19-convalescent, and identified antibodies that exhibited the comparable neutralizing ability to clinically used antibodies in the neutralization assay using pseudovirus and authentic virus including variants of concerns.
Journal ArticleDOI
A bivalent vaccine based on a replication-incompetent influenza virus protects against Streptococcus pneumoniae and influenza virus infection
Hiroaki Katsura,Zhenyu Piao,Kiyoko Iwatsuki-Horimoto,Yukihiro Akeda,Shinji Watanabe,Taisuke Horimoto,Kazunori Oishi,Yoshihiro Kawaoka +7 more
TL;DR: Reverse genetics is used to generate a replication-incompetent influenza virus carrying the sequence for the antigenic region of pneumococcal surface protein A and it is demonstrated that mice immunized with this virus were completely protected from lethal doses of infection with either influenza virus or Streptococcus pneumoniae.
Journal ArticleDOI
Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates
Ryuta Uraki,Shun Iida,Peter Halfmann,Seiya Yamayoshi,Yuichiro Hirata,Kiyoko Iwatsuki-Horimoto,Maki Kiso,Mutsumi Ito,Yuri Furusawa,Hiroshi Ueki,Yuko Sakai-Tagawa,Makoto Kuroda,Tadashi Maemura,Taksoo Kim,Sohtaro Mine,Noriko Iwamoto,Rongxiu Li,Yanan Liu,Deanna Larson,Shuetsu Fukushi,Shinji Watanabe,Ken Maeda,Zhongde Wang,Norio Ohmagari,James Theiler,Will Fischer,Bette T. Korber,Masaki Imai,Tadaki Suzuki,Yoshihiro Kawaoka +29 more
TL;DR: In this article , the authors evaluated the replicative ability and pathogenicity of BA.2.75 clinical isolates in Syrian hamsters and found no substantial differences in weight change among hamsters infected with BA.5 and BA.
letters-and-commentsDOI
Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate
Ryuta Uraki,Mutsumi Ito,Maki Kiso,Seiya Yamayoshi,Kiyoko Iwatsuki-Horimoto,Yuri Furusawa,Yuko Sakai-Tagawa,Masaki Imai,Michiko Koga,Shinya Yamamoto,Eisuke Adachi,Makoto Saito,Takeya Tsutsumi,Amato Otani,Tetsuhiro Kikuchi,Hiroshi Yotsuyanagi,Peter Halfmann,Andrew Pekosz,Yoshihiro Kawaoka +18 more